The management of thrombosis in pregnancy: Role of low-molecular-weight heparin

Summary Fatal pulmonary embolism remains the most common cause of mortality among pregnant women in many Western countries. The physiological changes of pregnancy produce a hypercoagulable state that increases the risk of venous thromboembolism (VTE).Women with inherited or acquired thrombophilias are at particularly high risk of VTE during pregnancy, and thromboprophylaxis may be advisable in some cases. Thrombophilia is also associated with complications of pregnancy, including fetal loss, pre-eclampsia, intra-uterine growth restriction, and placental abruption. The antithrombotic agents available for the prevention and treatment of VTE during pregnancy, and pregnancy complications, include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin. Vitamin K antagonists are contra-indicated in pregnancy. Low-dose aspirin may have a role in the prevention of some pregnancy complications, although its safety in early and late pregnancy is uncertain. The efficacy and safety of LMWHs have been demonstrated for the prevention and treatment of VTE in pregnancy. These agents are increasingly being used in place of UFH, which is associated with a higher incidence of side effects compared with LMWH, in addition to the need for regular laboratory monitoring. Evidence is also emerging to support the use of LMWH in the prevention of recurrent fetal loss, although further trials are needed to explore the role of LMWHs in this indication and in the prevention of other complications of pregnacy.

[1]  F. Spertini,et al.  Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. , 2006, Blood.

[2]  J. Gris,et al.  More on: factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case‐control ‘NOHA First’ study , 2006, Journal of thrombosis and haemostasis : JTH.

[3]  A. Wijesiriwardana,et al.  Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  I. Greer,et al.  Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.

[5]  B. Brenner,et al.  Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study , 2005, Journal of thrombosis and haemostasis : JTH.

[6]  J. Merlo,et al.  Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? , 2005, Journal of thrombosis and haemostasis : JTH.

[7]  H. Magnani,et al.  Treatment of 51 pregnancies with danaparoid because of heparin intolerance , 2004, Thrombosis and Haemostasis.

[8]  R. Zotz,et al.  Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications , 2004, Journal of thrombosis and haemostasis : JTH.

[9]  J. Gris,et al.  Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. , 2004, Blood.

[10]  C. Dempfle Minor transplacental passage of fondaparinux in vivo. , 2004, The New England journal of medicine.

[11]  A. Kaider,et al.  Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin , 2004, Thrombosis and Haemostasis.

[12]  L. Barbour,et al.  A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. , 2003, American journal of obstetrics and gynecology.

[13]  M. Khamashta,et al.  Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  C. Rodeck,et al.  Post-partum haemorrhage: definitions, medical and surgical management. A time for change. , 2003, British medical bulletin.

[15]  D. Back,et al.  A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy , 2003, Obstetrics and gynecology.

[16]  S. Kahn,et al.  Thrombophilic disorders and fetal loss: a meta-analysis , 2003, The Lancet.

[17]  D. Hoppensteadt,et al.  Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. , 2003, Hematology/oncology clinics of North America.

[18]  J. Kelton,et al.  Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System , 2003, Annals of Internal Medicine.

[19]  F. Stewart,et al.  Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series , 2002, BJOG : an international journal of obstetrics and gynaecology.

[20]  A. Eldor The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. , 2002, European journal of obstetrics, gynecology, and reproductive biology.

[21]  J. Wallace,et al.  Tissue Factor Expression on Monocyte Subpopulations during Normal Pregnancy , 2002, Thrombosis and Haemostasis.

[22]  R. Kaaja,et al.  Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. , 2002, Thrombosis research.

[23]  V. Hiilesmaa,et al.  Postpartum Bone Mineral Density in Women Treated for Thromboprophylaxis with Unfractionated Heparin or LMW Heparin , 2002, Thrombosis and Haemostasis.

[24]  Z. Miedzybrodzka,et al.  Prothrombotic Genotypes Are not Associated with Pre-eclampsia and Gestational Hypertension: Results from a Large Population-based Study and Systematic Review , 2002, Thrombosis and Haemostasis.

[25]  C. Jégo,et al.  Low Molecular Weight Heparins , 2012, Drugs.

[26]  A. Borel‐Derlon,et al.  Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies , 2001, BJOG : an international journal of obstetrics and gynaecology.

[27]  D. Henderson-smart,et al.  Antiplatelet agents for preventing and treating pre-eclampsia. , 2007, The Cochrane database of systematic reviews.

[28]  oseph,et al.  INCREASED FREQUENCY OF GENETIC THROMBOPHILIA IN WOMEN WITH COMPLICATIONS OF PREGNANCY INCREASED FREQUENCY OF GENETIC THROMBOPHILIA IN WOMEN WITH COMPLICATIONS OF PREGNANCY , 2000 .

[29]  D. Hoppensteadt,et al.  An update on heparins at the beginning of the new millennium. , 2000, Seminars in thrombosis and hemostasis.

[30]  V. Pettilä,et al.  Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. , 1999, Thrombosis research.

[31]  R. Venkataramanan,et al.  Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. , 1999, American journal of obstetrics and gynecology.

[32]  B. Brenner,et al.  Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review , 1999, Thrombosis and Haemostasis.

[33]  I. Greer Thrombosis in pregnancy: maternal and fetal issues , 1999, The Lancet.

[34]  J. Ray,et al.  Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. , 1999, Obstetrical & gynecological survey.

[35]  J. Bonnar,et al.  Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? , 1999, American journal of obstetrics and gynecology.

[36]  L. Duley Aspirin for preventing and treating pre-eclampsia , 1999, BMJ.

[37]  H. Cohen,et al.  Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin , 1999, British journal of obstetrics and gynaecology.

[38]  A. Many,et al.  Increased frequency of genetic thrombophilia in women with complications of pregnancy. , 1999, The New England journal of medicine.

[39]  M. Blombäck,et al.  A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  I. Greer,et al.  Activated Protein C Sensitivity, Protein C, Protein S and Coagulation in Normal Pregnancy , 1998, Thrombosis and Haemostasis.

[41]  H. Ostermann Low molecular weight heparins , 1998, Der Internist.

[42]  K. Maršál,et al.  Factor V Q506 Mutation (Activated Protein C Resistance) Associated with Reduced Intrapartum Blood Loss – a Possible Evolutionary Selection Mechanism , 1998, Thrombosis and Haemostasis.

[43]  M. Blombäck,et al.  Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[44]  B. Brenner,et al.  Thrombophilia and Fetal Loss , 2003, Blood reviews.

[45]  H. Geijn,et al.  Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies , 1997, British journal of obstetrics and gynaecology.

[46]  I. Greer,et al.  An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy , 1997, British journal of obstetrics and gynaecology.

[47]  H. Cohen,et al.  Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) , 1997, BMJ.

[48]  W. Kutteh Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. , 1996, American journal of obstetrics and gynecology.

[49]  R. Farquharson,et al.  Bone density studies in pregnant women receiving heparin. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[50]  J. T. ten Cate,et al.  The Risk of Abortion and Stillbirth in Antithrombin-, Protein C-, and Protein S-deficient Women , 1996, Thrombosis and Haemostasis.

[51]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[52]  V. Kakkar,et al.  Long‐term administration of heparin and heparin fractions and osteoporosis in experimental animals , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[53]  H. Sjöberg,et al.  Bone mineral density during long‐term prophylaxis with heparin in pregnancy , 1994, American journal of obstetrics and gynecology.

[54]  J. Steiner,et al.  A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. , 1994, American journal of obstetrics and gynecology.

[55]  T. Brighton,et al.  Antiphospholipid antibodies and thrombosis. , 1994, Bailliere's clinical haematology.

[56]  A. Kher,et al.  Low Molecular Weight Heparin as Thromboprophylaxis in Pregnancy , 1994 .

[57]  K. Nicolaides,et al.  Use of Low Molecular Weight Heparin in Pregnancy , 1992, Thrombosis and Haemostasis.

[58]  Jeffrey S. Ginsberg,et al.  Use of antithrombotic agents during pregnancy. , 1992, Chest.

[59]  R. Silver,et al.  Outcome of Treated Pregnancies in Women With Antiphospholipid Syndrome: An Update of the Utah Experience , 1992, Obstetrics and gynecology.

[60]  J. Denburg,et al.  Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. , 1992, Blood.

[61]  J. Denburg,et al.  The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study , 1991, Thrombosis and Haemostasis.

[62]  N. Lindvall,et al.  Osteopenia in pregnancy during long‐term heparin treatment: A radiological study post partum , 1991, British journal of obstetrics and gynaecology.

[63]  H. Lawson,et al.  Maternal Mortality in the United States, 1979-1986 , 1990, Obstetrics and gynecology.

[64]  M. Levine,et al.  Risks to the Fetus of Anticoagulant Therapy During Pregnancy , 1989, Thrombosis and Haemostasis.

[65]  P. Mombaerts,et al.  Fibrinolytic Response to Venous Occlusion and Fibrin Fragment D-Dimer Levels in Normal and Complicated Pregnancy , 1987, Thrombosis and Haemostasis.

[66]  D. Bergqvist,et al.  Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. , 1986, British journal of obstetrics and gynaecology.

[67]  B. Åstedt,et al.  Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma , 1986, British journal of haematology.

[68]  I. Nilsson,et al.  Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women , 1986, British journal of haematology.

[69]  T. Meade,et al.  Haemostasis in Normal Pregnancy , 1984, Thrombosis and Haemostasis.

[70]  M. Blombäck,et al.  Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. , 1981, Gynecologic and obstetric investigation.

[71]  B. Bjerre,et al.  Maternal Mortality in Sweden , 1964, Acta obstetricia et gynecologica Scandinavica.

[72]  G. Lennon,et al.  Primary postpartum haemorrhage , 2002, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.